One in Five American Workers Tested Had a Positive Hair Drug Test in 2025, Signaling Persistent Long-Term Substance Use Patterns

Quest Diagnostics’ 2026 Drug Testing Index finds general U.S. workforce hair drug positivity rose to 19.1% in 2025 (from 13.1% in 2021, +46%), with marijuana accounting for 15.1% of hair positives (+58.9% vs 2021). Urine positivity was 4.3% in 2025 (slightly down from 4.4% in 2024), while fentanyl positivity fell nearly half to 0.28% (from 0.55%). The article also notes a regulatory push in April 2026 to reclassify medical marijuana from Schedule I to Schedule III, which could affect cannabis testing in federal programs.

Analysis

The economic read-through is less about drug prevalence and more about employer behavior: when the cost of a bad hire or workplace incident rises, companies buy more tamper-resistant, higher-ASP screening and more frequent random/post-accident testing. That is structurally favorable for DGX’s workforce mix because hair and oral-fluid protocols are stickier than urine and tend to pull through more compliance services per employee; smaller urine-only vendors should feel the pressure first. If this persists, the margin impact should be better than the headline volume effect because mix shift, not just unit growth, is what expands value.

The main risk is regulatory, but the timing is slow. Any federal cannabis reclassification would likely hit first in government and federally contracted workforces, then filter into private employer policy over 6-18 months; that is a policy process, not a same-quarter earnings shock. Near term, a safety incident, union contract change, or insurer-employer push for stronger impairment controls is the more likely catalyst for another leg of testing demand. Falsifier: management commentary showing Workplace Health volumes flat-to-down despite elevated positivity, or evidence that employer cannabis policy loosening accelerates faster than expected.

Contrarianly, the market may be underestimating how little marijuana normalization matters to safety-sensitive employers. Legal status and workplace tolerance are different variables; in transportation, healthcare, and retail operations, adverse-event risk often drives stricter testing regardless of state policy. MJNA-style cannabis equities only benefit if reclassification actually improves financing, distribution, and consumer adoption; that is a separate, slower thesis and not the same as workplace impairment economics.

Key Decisions for Investors

• Long DGX on weakness over the next 1-2 sessions; target 3-5% relative outperformance over 1-3 months as the market prices a better Workplace Health mix. Invalidate if management signals occupational testing deceleration or weaker guidance.
• Pair trade: long DGX / short LH for 1-3 months. DGX has the cleaner lever to compliance-driven testing mix, while LH is less directly exposed; seek 5-8% spread compression with limited macro beta.
• Do not chase MJNA on this print. Wait for actual federal scheduling language and employer policy updates; absent those, the stock is more headline beta than monetizable earnings leverage.
• Set a watch item on federal contractor testing guidance and DOT-related policy. If reclassification starts to reduce mandated testing, cut DGX exposure quickly; that is the clearest medium-term downside catalyst.